BR3, expressed on all mature B cells, is a specific receptor for the B cell survival and maturation factor BAFF (B cell-activating factor belonging to the TNF family). In order to investigate the consequences of targeting BR3 in murine models and to assess the potential of BR3 antibodies as human therapeutics, synthetic antibody phage libraries were employed to identify BAFF-blocking antibodies cross-reactive to murine and human BR3, which share 52% identity in their extra-cellular domains. An antibody, CB1, was found, which exhibits μM affinity for murine BR3, and very weak affinity for the human receptor. CB3s, an affinity-matured variant of CB1, has sub-nM affinity for BR3 from both species. Alanine scanning and crystallographic structural analysis of the CB3s/BR3 complex reveal that CB3s mimics BAFF by interacting with a similar region of the BR3 surface. Despite this similarity in binding epitopes, CB1 variants antagonize BAFF-dependent human B cell proliferation in vitro and are effective at reducing murine B cell populations in vivo, showing significant promise as therapeutics for human B-cell-mediated diseases.
Introduction
BR3 (BAFF/BLyS receptor 3, also known as BAFF-R) was originally identified as a BAFF-specific receptor, important for B cell survival in mice 1, 2 . BR3 is expressed on all mature B cells, and at very low levels on activated T cells 3 . BR3 expression is also maintained in many B cell malignancies, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia 4 . BAFF (also known as BLyS, TALL-1, zTNF-4, THANK, TNFSF13b) is a member of the TNF ligand superfamily and is capable of binding not only BR3, but also two other receptors, TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) and BCMA (B cell maturation antigen), both of which can also bind the related ligand APRIL (a proliferation-inducing ligand) 5, 6 . BAFF over-expression in mice induces B cell hyperplasia and manifestations of autoimmune disease, while BAFF-knockout mice show near complete absence of mature B cells. In humans, elevated levels of BAFF are found in a subset of patients with Sjögren's syndrome, rheumatoid arthritis, and systemic lupus erythematosus and correlate with disease severity [7] [8] [9] . Elevated BAFF levels have also been reported in patients with diffuse large B cell lymphoma and correlate with poorer clinical outcome 4 . Consequences of ligand-directed BAFF-blockade have been investigated in autoimmune disease models, showing significant efficacy in mouse models of lupus 10 and rheumatoid arthritis 11, 12 . Several BAFF-targeted agents are currently being pursued in clinical development for both autoimmune disease and hematological malignancies [13] [14] [15] .
However, BR3 is the principal receptor responsible for mediating BAFF-dependent B cell survival effects [1] [2] [3] 16 . Thus, targeting BR3 directly with an antibody, unlike the For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From 4 ligand-directed approaches, would disrupt the BAFF/BR3 axis specifically and leave BAFF free to signal through its other receptors. TACI was originally thought to act as an inhibitory receptor 17 , however recent reports suggest that TACI could induce both positive and negative signals in B cells 18, 19 . The function of BCMA is less clear, however it appears to play a role in long-lived plasma cell survival 20 . Hence, the ability to compare agents specific for BR3 with those impacting other BAFF/receptor interactions in vivo will be valuable in furthering our understanding of this complex signaling pathway, and may have important impact on pharmaceutical development strategies.
Desired features of a therapeutic BR3 antagonistic antibody include the ability to bind BR3 with high-affinity, prevent BAFF/BR3-binding, while importantly not triggering BR3
signaling and B cell survival on its own. Agonistic antibodies that activate other members of the TNF receptor family, due to the bivalent nature of IgG (immunoglobulin), have been described for TNFR, Fas, DR5, CD40 and CD137 [21] [22] [23] [24] [25] . Further, developing a cross-reactive antibody that binds both murine (mBR3) and human BR3 (hBR3) [52% identity in their extracellular domains (ECD)s 1, 2 ] would be useful given that the in vivo effects and mechanisms of action of such an antibody could be evaluated in detail in murine models prior to clinical trials in humans. Antagonistic anti-hBR3 mAbs that inhibit BAFF-mediated B cell proliferation in vitro have been described previously 3 , however these mAbs were obtained by hybridoma technology and were not cross-reactive between species, not surprising given that mice remove self-reactive antibodies 26 . Herein, we describe the use of phage-displayed synthetic antibody libraries 27 to identify a lead parental antibody and optimize its affinity to 5 BR3 from both species, without prior knowledge of the binding paratope. Structural and functional studies of BR3 in complex with the cross-reactive antibody reveal the mechanism by which the antibody binds BR3 from both species and prevents BAFF-binding. Finally, antagonistic activities of the phage-derived antibody are characterized in vitro with primary human B cells and in vivo in mice to reinforce the validity of such an antibody as a potential treatment for B-cell-mediated diseases.
RESULTS

Discovery of a phage-derived anti-BR3 BAFF-blocking antibody
Synthetic antibody libraries which allow for bivalent display of Fab fragments on M13 phage 27, 28 were employed for initial identification of BR3-binding antibodies. The antibody libraries were generated by randomizing 17 residues in the heavy chain complementarity-determining regions (CDR)s on the humanized anti-erbB2 antibody 4D5
(h4D5) template in a manner that mimics the diversities of natural antibodies. Four unique clones (CB1, CB1a, CB1b, CB1c) were identified by selecting for binding to mBR3-ECD; no clones were identified by selection for binding to hBR3. All four clones showed modest micromolar binding affinities to mBR3 in competition phage ELISA, however CB1 had the greatest ability to compete with BAFF for BR3-binding ( Figure 1A ). Full-length IgG versions were generated to utilize increased avidity to detect weak binding. CB1-IgG was the only antibody showing any detectable binding to hBR3 ( Figure 1B ).
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Affinity improvement for binding to both mBR3 and hBR3
To improve the affinity of CB1 for both murine and human BR3, four different combinations of CDR loops were targeted for randomization: L1/L2/L3, L2/L3/H1, L3/H3, and L3/H1/H2
( Figure 2A ). The strategy of co-evolving several CDR loops together allows for simultaneous optimization of the CDR-antigen and CDR-CDR interactions, as it was observed previously that combining independently optimized CDRs often results in non-additivity and reduced affinities 29 . CDR residues were selected for randomization using a structure-guided strategy of choosing surface-accessible residues 27 . In designing the diversity for targeted positions, we used restrictive codons for residues in CDR-L1, -L2, and -L3 to mimic the diversity in natural antibodies as described 27 , or a strategy of "soft randomization" for CDR-H1, -H2, -H3, and -L3 30, 31 , in which the selected residues were mutated to non-wild-type residues or maintained as wild type at ~50:50 frequency. The CDR-H3 loop of CB1 contains 15 residues including a pair of cysteines. The cysteine pair was excluded from randomization as mutation of these residues was found to entirely disrupt the already weak binding (data not shown).
Through stringent selection for binding to mBR3 or hBR3, followed by screening for cross-reactivity, three unique variants (CB2, CB2a, CB2b) were isolated from the CDR-L3/H3 library and one variant (CB2c) from the CDR-L2/L3/H1 library by selecting against mBR3 (as before, hBR3 selections yielded no enrichment). All variants showed improved affinity to mBR3, but with different extents of cross-reactivity ( Figure 2B ). CB2
with alterations in CDR-L3 (Y92R, T93I) and CDR-H3 (S99N, S100R, V100 a L, R100 b G, 7 G100 c V, A100 g G) appeared to be the best clone, exhibiting single-digit nM affinity (ELISA, IC 50 ) for mBR3 and hBR3, representing over 200-and 1000-fold affinity improvement, respectively ( Figure 2B, Supplementary Figure 1) . Note that selection for improved binding to mBR3, also resulted in improved binding to hBR3, suggesting that CB2 recognize a region of BR3 conserved across species.
To further improve the affinity of CB2, the CDR loop combinations of L3/H3 or L3/H1/H2 were randomized using a similar strategy as above. Interestingly, the CDR-L3/H3
library did not show enrichment in this round of affinity selection, suggesting further mutations of these two loops are mainly disruptive. In contrast, many affinity-improved variants were identified from the CDR-L3/H1/H2 library, based on selecting for binding to either hBR3 or mBR3. Among the variants, CB3, mutated at CDR-L3 (R92Q, T94S) and CDR-H1 and -H2 (N32S, I51V, T52L, D54V, N56F) showed improved binding to mBR3 and hBR3 by 3-and 10-fold, respectively. However, a potential N-linked glycosylation site was generated in the CB3 CDR-H1 sequence for residues 31-33 (N-S-S). Hence, mutant CDR-H1-N31S, named CB3s, was engineered to remove the glycosylation site, and showed improved binding compared with CB3, when expressed from mammalian cells. CB3s-Fab bound mBR3 and hBR3 with affinities of 1 and 0.6 nM (K D ), respectively ( Figure 2B ).
Mapping anti-BR3 binding sites on hBR3
The 26-residue core of hBR3 (miniBR3, residues 17-42) contains a well-structured β-hairpin, and was shown to maintain equivalent BAFF-binding affinity as the full-length BR3-ECD 10 . A set of substitutions (F25A, D26A, V33A, A34G) showed significant loss (F ≥ 10) in binding for all four antibodies and BAFF. While this could indicate that these residues contribute directly to the interaction with all of the binders, a more plausible explanation is that these substitutions disrupt the conformational integrity of the BR3 molecule and thus indirectly affect binding. Indeed, the F25A mutation was previously identified as one that likely destabilizes BR3 structure 32 . Other substitutions affect only a subset of binders and are likely to reveal specific contacts that define distinct epitopes as highlighted on the structure of miniBR3 in Figure 3B . Note that the hybridoma-derived antibodies appear to utilize 9 non-conserved residues, accounting for their lack of cross-reactivity between species. Figure 3C ). These residues are conserved in hBR3 and mBR3, and similarly BAFF itself is capable of binding tightly to both hBR3 and mBR3 2 .
As BAFF also interacts with two other receptors, BCMA and TACI, which contain similar conserved sequences and structures in their respective β-turn regions ( Figure 3C ) 34 Figure 2) . Thus CB2 cross-reacts with human and murine orthologues of BR3, but does not bind other BAFF receptors.
Structure of the CB3s/hBR3 complex
To investigate the molecular basis of BAFF-blocking and cross-species binding of CB1 variants, the crystal structure of CB2-Fab alone and a complex between CB3s-Fab and a hBR3 variant (residues 7-54) were determined at 1.95 and 2.6 Å resolution, respectively (Table 1) . Variant hBR3 has two changes relative to hBR3 (L27P and V20N). These changes replace human residues with their murine counterparts and result in improved BR3 expression and folding efficiency 36 , while maintaining high-affinity BAFF and CB3s-binding. The structure of CB2-Fab alone adopts a typical Fab conformation except for CDR-H3, which is disordered beyond the disulfide. In the CB3s/BR3 complex, the entire CDR-H3 loop is 10 well-ordered, suggesting this long loop becomes stabilized by BR3 binding. In this structure, the BR3 DxLV motif binds CB3s in a manner very similar to its interaction with BAFF ( Figure 4) ; the interaction centers on L28 and V29 of BR3, which binds in a hydrophobic pocket on CB3s created by the juncture of CDR-H2 and -L3 loops ( Figure 5A ). D26 of BR3
forms a salt bridge to R95 of CDR-H3, which mimics the salt bridge between D26 and BAFF residue R265 observed in structures of BAFF with different receptors or receptor fragments ( Figure 4 ) 32, 33, 35, 37 . Unlike the relatively focused epitope between BR3 and BAFF which buries ~1000 Å 2 in accessible surface area on complex formation, the CB3s/hBR3 interface is much larger (~1600 Å 2 ). In the BAFF/BR3 structure, the only residues that significantly contact BAFF outside of the β-turn region are V33 and L38. In contrast, residues 31-38 all contact CB3s-Fab. Thus, CB3s blocks BAFF by utilizing an epitope that completely encompasses the BAFF-binding site on BR3.
Mapping hBR3 and mBR3 binding sites on CB3s
Next, we wanted to understand how CB3s accommodates binding to both hBR3 and mBR3, which differ substantially in sequence. Shotgun-alanine-scanning mutagenesis, which varies CB3s CDR residues between wild type or alanine, and shotgun-homolog-scanning, which varies CDR residues between wild type or a homologous amino acid, were performed in order to measure the contribution of individual side chains, or the requirement for a specific side chain, respectively 38 . F values indicating the preference of the wild type residue over the mutation for each varied position were calculated and tabulated (Supplementary Figure 3) .
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Results from alanine-scanning for both hBR3 and mBR3 binding are shown on the structure of CB3s-Fab with coloring according to the functional importance for each residue ( Figure   5B -C). Overall, the paratope mapped by shotgun-scanning mutagenesis is highly consistent with the structural interface ( Figure 5A ). While some of the residues showing disruptive mutations do not make direct contact with BR3, most of the highly important side chains (F > 10) make extensive contact with the receptor.
A set of residues, which are similarly important for binding to hBR3 and mBR3 (F > 10 when substituted by alanine) make up a common "hot spot" Figure 3) . Notably, most of these hot spot residues already exist in the parental clone CB1, suggesting that this region confers the main binding energy in the initial clone before affinity improvement. Three residues, L52 (CDR-H2), G100b (CDR-H3) and S94 (CDR-L3), altered during subsequent affinity maturation, likely contribute to improving binding affinities. The differences between human and murine BR3 in this portion of the interface (L27P, H31N; human vs murine residue) appear to be accommodated equally.
In contrast, a set of CDR-H3 residues of CB3s (Y98, N99, R100, A100e) that interact with the "C-terminal tail" of BR3 (residue 34-38) are functionally more important for mBR3-12 than for hBR3-binding, while some CDR-L2 residues (Y49, F53) interacting with the same segment of BR3 are functionally more important for hBR3-than for mBR3-binding ( Figure   5B -C, Supplementary Figure 3) . Interestingly, the alteration of these residues in CDR-H3 appears to be the key to switch the specificity from the mostly mBR3-selective CB1 to the equally cross-reactive CB2; CB2c, retaining the CB1 CDR-H3, is not nearly as cross-reactive to hBR3 as CB2.
The property of cross-species binding by CB3s appears to be achieved first by utilizing a common hot-spot binding interaction with conserved residues in the BR3 β-hairpin, in a similar manner as BAFF does, and second by being able to also accommodate the rest of the molecule and differentially distribute the binding energy toward residues that differ between species. CB1 was initially discovered by panning for binders to mBR3; thus, the observation that the binding site appears to "fit" mBR3 better than hBR3 is not surprising. As the binding site evolved, mutations appeared to have been selected that better accommodate hBR3 binding rather than introducing new hBR3-specific interactions.
Antagonism of BAFF-dependent activities in vitro
BAFF was previously shown to co-stimulate primary human B cell proliferation in the presence of anti-IgM 40 ; such BAFF-dependent proliferation could be blocked by BAFF-receptor fusion proteins or anti-BR3 mAbs 3 . To establish whether these cross-reactive antibodies trigger or block BR3 signaling, a similar assay format was utilized. Both CB2-IgG 
DISCUSSION
Herein we describe an antagonistic BR3 antibody, CB1, identified from antibody phage libraries by initally screening for a Fab-displaying phage clone that competed for mBR3 binding to BAFF. CB1 was then improved to bind hBR3 and mBR3 with equally high affinity by altering residues from several CDR loops. This property of cross-species binding is a benefit of generating antibodies via in vitro panning processes that clearly use different rules for selecting epitopes compared to hybridoma technologies 42 . We show that the improved CB1
variants, CB2 and CB3s, bind BR3 in a manner that mimics how the ligand BAFF binds BR3 15 both structurally and functionally, indicating that the BR3 epitope evolved in vivo for binding its natural biological partner is also a "hot-spot" targeted by in vitro selection. The cross-species high-affinity binding of CB3s is due mainly to interactions with this conserved hot spot.
However, additional residue substitutions selected during affinity maturation were necessary to better accomodate other regions of the receptor, where sequence differences occur between species. This mechanism of high affinity binding and specificity determination is reminiscent of other protein-protein interactions where the energetic hot-spot, which is often conserved, and the site determining specificity are distinct 43 .
Clinical 
METHODS
Phage library selection for BR3-binding clones. Phage-displayed synthetic antibody libraries were generated using oligonucleotide-directed mutagenesis in the three heavy chain
CDRs on a modified h4D5-encoding phagemid, pV350-4, as template, and described as Lib-3 27 . BR3-ECD was expressed in E. coli and purified as described 10 . For initial selection with the naïve libraries, mBR3-ECD, and hBR3-ECD were immobilized on Maxisorp immunoplates and phage libraries were cycled through four rounds of binding selection 27 .
Random clones selected from rounds 3 and 4 were picked and assayed to identify specific binders using phage ELISA. The V H regions of selected clones were amplified by PCR for sequencing.
Competition phage ELISA. Phage clones were propagated from a single colony by growing in 30 ml of 2YT culture supplemented with carbenicillin and KO7 helper phage overnight at 17 30°C, purified, and assayed as described 27, 42 . Antibody phage libraries for affinity maturation. To create the phage template for affinity improvement, the GCN4 leucine zipper of the CB1 phagemid was first removed by Kunkel mutagenesis to provide a monovalent display format, and a stop codon (TAA) was incorporated in all CDR-L3 positions targeted for randomization. In the natural antibody-mimicking light chain library, the degeneracy design was as described 27 . In the soft randomization libraries, positions 91, 92, 93, 94 and 96 of CDR-L3, 31-33 of CDR-H1, 49-58 of CDR-H2, and the front half (95-100c), last half (99-100g) or the whole section (95-100g) of CDR-H3 except the two cysteines (position 97, 100d) were coded with degenerate oligonucleotides. To achieve the soft randomization conditions, the mutagenic DNA was synthesized with 70-10-10-10 mixtures of bases favoring the wild type nucleotides 46 . In the improvement of CB2, "stop" codons were again incorporated in the CDR-L3 of the template and "softer" randomization of CDR-H3 was included; mutagenic oligonucleotides were synthesized as 85-5-5-5 mixtures of bases.
Solution-phase sorting and screening for affinity improvement. A solution-phase sorting method was used to enhance the efficiency of affinity-based selection as described 27 . Phage libraries were incubated with biotinylated mBR3-ECD or hBR3-ECD for 2 hr at room temperature in PBS with 0.05% (v/v) Tween20, and 0.5% Superblock (Pierce) (PST). The mixture was diluted 5-10-fold with PST and incubated with immobilized neutravidin for 5-10-min to capture phage bound to the biotinylated mBR3-ECD or hBR3-ECD. Libraries were cycled through 3-4 rounds of selection with decreasing concentrations of biotinylated mBR3-or hBR3-ECD. In the last round of selection, 1000-fold excess of non-biotinylated mBR3-or hBR3-ECD was added to compete for binding at 37°C for 30 min before capturing on neutravidin-coated wells. A high-throughput, single-point competition ELISA was then used to screen for high-affinity clones as described 47 . Competition phage ELISAs with purified phage were used to identify affinity improvements.
Fab and IgG production. To generate Fab or IgG proteins for characterization, the variable domains of selected phage clones were cloned into vectors designed for Fab expression in E.
coli as described 27 or pRK5 based plasmid with human or murine light chain or heavy chain (human IgG1 or murine IgG2a) constant domain for transient IgG expression in Chinese
Hamster Ovary (CHO) cells. Fab protein was generated by growing the transformed 34B8 E.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From coli cells in AP5 medium at 30°C for 24 hr and purified using protein G affinity chromatography 27 . Full length IgG proteins were purified using protein A, followed by ion exchange chromatography, and quantified by amino acid analysis. Protein purification and crystallization for structure determination. A BR3 expression construct was generated by cloning a gene fragment encoding S7-A54 of hBR3-ECD and a tyrosine at the amino-terminus (to add cloning site) into XbaI/BamHI sites of the expression vector, pET-32a (Novagen), which was modified to delete the S-Tag and enterokinase site.
Residues V20 and L27 were mutated to mBR3 sequence (N20 and P27) to improve protein production efficiency 36 . Origami (DE3) competent cells (Novagen) transformed with pET32a-BR3-ECD were grown with IPTG induction overnight at 16°C. BR3 cell pellets were lysed in 20 mM CAPS, pH 9.7, 400 mM NaCl by microfluidization. Cell supernatant was eluted from a Ni-NTA agarose column (Qiagen) in buffer containing 50 mM imidazole.
Protein was then passed over a S75 sizing column, the thioredoxin-His-tag was removed by thrombin cleavage, and un-tagged BR3 was further purified on a S75 sizing column. The expression and purification of CB3s-and CB2-Fab in E. Coli were as described 27, 42 .
For complex formation for crystallization, BR3 and CB3s-Fab were mixed at a 3:1 molar ratio, and purified over a S75 sizing column in 20 mM MES, pH 6.0, 50 mM NaCl 24% PEG 3350 and 100 mM Praseodymium (III) acetate with 20% dextrose. CB2-Fab was purified as described for CB3s-Fab except that the buffer for the final column was 25 mM MES pH 6.0, 100 mM NaCl. The sample was concentrated to 11 mg/mL. Crystals were grown in hanging drops with 1:1 ratio of protein to well solution consisting of 100 mM Hepes, pH 7.5, 20% PEG 10K, and then frozen in mother liquor with 25% PEG 400.
Crystallography. The CB2 crystals belong to space group P1. A 1.95 Å data set was collected at beamline 19ID at the Advanced Photon Source and processed with HKL ( Table 1 ). The structure was solved by molecular replacement using the humanized 4D5 Fab (pdb code 1FVE). For
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To evaluate the antagonistic effects of anti-BR3 antibodies (all in hIgG1 format), B cells (1 x   10 5 /well) were incubated with soluble recombinant BAFF (10 ng/ml) and an F(ab') 2 goat anti-human IgM (Fc specific) antibody (4 µg/ml) (Jackson ImmunoResearch, West Grove, PA)
in the presence and absence of various concentrations of anti-BR3 antibody. The same assay format, with the exception that BAFF is omitted, was utilized to assess potential agonistic effects. B cell proliferation was assessed at day 6 by adding Celltiter Glo (Promega, Madison, WI.) The plates were then read in a luminometer after a 10-min incubation at room temperature.
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